Inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, is a chronic inflammatory condition of the intestine and one of etiological factor for colon cancer development. Incidences of inflammatory bowel disease is still high around the world, even with current therapy, emerging the need for innovational approach to increase the achievement of disease improvement and remission. Curcumin is a natural compound derived from Curcuma longa and has been well known with its anti-inflammatory properties which is possible to be beneficial for inflammatory bowel disease. This review aims to provide clinical evidences of effectively and safety profile of curcumin in treating inflammatory bowel disease, both Crohn’s disease and ulcerative colitis, and viewing the future prospect of curcumin to be an effective adjuvant therapy to prevent the relapse of inflammatory bowel disease.
{"title":"Clinical and Endoscopic Improvement of Inflammatory Bowel Disease with Curcumin Therapy: Experiences from Clinical Studies","authors":"William Suciangto, Munaiva Syahrir","doi":"10.24871/2332022241-249","DOIUrl":"https://doi.org/10.24871/2332022241-249","url":null,"abstract":"Inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, is a chronic inflammatory condition of the intestine and one of etiological factor for colon cancer development. Incidences of inflammatory bowel disease is still high around the world, even with current therapy, emerging the need for innovational approach to increase the achievement of disease improvement and remission. Curcumin is a natural compound derived from Curcuma longa and has been well known with its anti-inflammatory properties which is possible to be beneficial for inflammatory bowel disease. This review aims to provide clinical evidences of effectively and safety profile of curcumin in treating inflammatory bowel disease, both Crohn’s disease and ulcerative colitis, and viewing the future prospect of curcumin to be an effective adjuvant therapy to prevent the relapse of inflammatory bowel disease. ","PeriodicalId":22564,"journal":{"name":"The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80287855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fauzan Hertrisno Firman, Gerald Abraham Harianja, H. Maulahela
Aim: To determine the preferred method of treatment in patients with choledocholithiasis after endoscopic retrograde cholangiopancreatography (ERCP) by evaluating efficacy of early laparascopic cholecystectomy compared to delayed laparoscopic cholecystectomy.Method: Literature searching was carried out on two databases, PubMed and Cochrane, according to the inclusion and exclusion criteria. Two randomized clinical trial (RCT) studies were appraised critically for validity, importance, and applicability.Results: Early laparascopic cholecystectomy after ERCP shows lower outcomes in incidence of recurrent choledocholithiasis, acute cholecystitis, duration of hospitalization, and treatment costs (p 0.05). Meanwhile, there was no significant difference (p 0.05) between the two groups regarding the incidence of biliary adhesions, bleeding during cholecystectomy, and laboratory parameters such as total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma glutamyl transferase (GGT).Conclusion: Early cholecystectomy, within three days after ERCP, is recommended for the treatment of choledocholithiasis after ERCP removal.
{"title":"Early Versus Delayed Laparoscopic Cholecystectomyafter Endoscopic Retrograde Cholangio-Pancreatography (ERCP) Removal of Choledocholithiasis: An Evidence-based Case Report","authors":"Fauzan Hertrisno Firman, Gerald Abraham Harianja, H. Maulahela","doi":"10.24871/2332022259-263","DOIUrl":"https://doi.org/10.24871/2332022259-263","url":null,"abstract":"Aim: To determine the preferred method of treatment in patients with choledocholithiasis after endoscopic retrograde cholangiopancreatography (ERCP) by evaluating efficacy of early laparascopic cholecystectomy compared to delayed laparoscopic cholecystectomy.Method: Literature searching was carried out on two databases, PubMed and Cochrane, according to the inclusion and exclusion criteria. Two randomized clinical trial (RCT) studies were appraised critically for validity, importance, and applicability.Results: Early laparascopic cholecystectomy after ERCP shows lower outcomes in incidence of recurrent choledocholithiasis, acute cholecystitis, duration of hospitalization, and treatment costs (p 0.05). Meanwhile, there was no significant difference (p 0.05) between the two groups regarding the incidence of biliary adhesions, bleeding during cholecystectomy, and laboratory parameters such as total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma glutamyl transferase (GGT).Conclusion: Early cholecystectomy, within three days after ERCP, is recommended for the treatment of choledocholithiasis after ERCP removal.","PeriodicalId":22564,"journal":{"name":"The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78392328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aim: This evidence-based case report aims to assess the accuracy of EUS-PPG measurement in patients with portal hypertension.Method: A literature search was performed using PubMed, Cochrane, ProQuest, and EBSCO. A total of 2 articles were selected after meeting the inclusion and exclusion criteria. Critical study assessment was conducted to assess the validity, importance, and applicability of the study.Results: As a result, the first study found higher EUS-PPG measurement values in patients with clinical parameters of portal hypertension and the second study found a good correlation between EUS-PPG measurement values with hepatic vein pressure gradient (HVPG) and transjugular intrahepatic portosystemic shunt (TIPS) portal pressure gradient (PPG).Conclusion: From these two studies, it can be concluded that EUS-PPG measurement is a safe, effective, and feasible method to be performed on patients.
{"title":"EUS-Guided Portal Pressure Gradient Measurement in Patients with Portal Hypertension: Evidence-Based Case Report","authors":"Putra Nur Hidayat, Juferdy Kurniawan","doi":"10.24871/2332022254-258","DOIUrl":"https://doi.org/10.24871/2332022254-258","url":null,"abstract":"Aim: This evidence-based case report aims to assess the accuracy of EUS-PPG measurement in patients with portal hypertension.Method: A literature search was performed using PubMed, Cochrane, ProQuest, and EBSCO. A total of 2 articles were selected after meeting the inclusion and exclusion criteria. Critical study assessment was conducted to assess the validity, importance, and applicability of the study.Results: As a result, the first study found higher EUS-PPG measurement values in patients with clinical parameters of portal hypertension and the second study found a good correlation between EUS-PPG measurement values with hepatic vein pressure gradient (HVPG) and transjugular intrahepatic portosystemic shunt (TIPS) portal pressure gradient (PPG).Conclusion: From these two studies, it can be concluded that EUS-PPG measurement is a safe, effective, and feasible method to be performed on patients.","PeriodicalId":22564,"journal":{"name":"The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80908568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chilaiditi’s syndrome is a rare disease with an incidence of 0.025-0.28% cases, where it shows colon interposition between diaphragm and right lobe of liver. Usually related to congenital malformation include the absence, weakness, or elongation of suspensory ligaments of transversal colon or falciform ligaments. The 83-year-old woman was admitted with 1-week history of fatigue, lacked the will to eat and drink. Nausea and vomiting were sometimes accompanied with abdominal pain. Patient often had difficulty in defecating even though she had been eating fruits, she often needed laxatives. Patient had a history of osteoarthritis and hypertension.Physical examination appeared moderately-ill, with gasglow coma scale (GCS) 14 and blood pressure 150/90 mmHg. From abdomen epigastric tenderness (+). From thoracic X-ray found visible interposition of colon at right-upper quadrant of abdomen. Geriatric index fall risk assessment = 11 and mini mental state examination (MMSE) = 22. This patient was a geriatric patient with multiple diagnosis and frailty. Patient had a history of osteoarthritis contributes to patient’s instability. Chronic constipation was also quite disturbing cause an interposition of colon. Patient had coincidence with COVID-19 with comorbidity and geriatric syndrome. Thorough care, close monitoring, and optimal management should be applied.
{"title":"Accidentally Case of Chilaiditi’s Syndrome in COVID-19 Geriatric Patient","authors":"Vesri Yoga, M. Abdullah, Arnelis Arnelis","doi":"10.24871/2332022250-253","DOIUrl":"https://doi.org/10.24871/2332022250-253","url":null,"abstract":"Chilaiditi’s syndrome is a rare disease with an incidence of 0.025-0.28% cases, where it shows colon interposition between diaphragm and right lobe of liver. Usually related to congenital malformation include the absence, weakness, or elongation of suspensory ligaments of transversal colon or falciform ligaments. The 83-year-old woman was admitted with 1-week history of fatigue, lacked the will to eat and drink. Nausea and vomiting were sometimes accompanied with abdominal pain. Patient often had difficulty in defecating even though she had been eating fruits, she often needed laxatives. Patient had a history of osteoarthritis and hypertension.Physical examination appeared moderately-ill, with gasglow coma scale (GCS) 14 and blood pressure 150/90 mmHg. From abdomen epigastric tenderness (+). From thoracic X-ray found visible interposition of colon at right-upper quadrant of abdomen. Geriatric index fall risk assessment = 11 and mini mental state examination (MMSE) = 22. This patient was a geriatric patient with multiple diagnosis and frailty. Patient had a history of osteoarthritis contributes to patient’s instability. Chronic constipation was also quite disturbing cause an interposition of colon. Patient had coincidence with COVID-19 with comorbidity and geriatric syndrome. Thorough care, close monitoring, and optimal management should be applied.","PeriodicalId":22564,"journal":{"name":"The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy","volume":"436 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76226209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ika Dhuhani, D. Handjari, N. Rahadiani, E. Krisnuhoni, Marini Stephanie
Background: Colorectal adenocarcinoma (CA) is one of the most common malignancies. Tumor budding (TB) status is associated with poor prognosis in patients. Prognosis is influenced by the clinicopathological profile. This study aims to determine the relationship between the clinicopathological profile with TB status in CA at Dr. Cipto Mangunkusumo General National Hospital.Method: A cross-sectional retrospective analytic study using secondary data in the form of cases in large bowel malignancy resection preparations at the Department of Anatomical Pathology in 2019-2021. A total of 213 samples were taken from all cases according to the inclusion and exclusion criteria. Chi square statistical analysis was performed to see the clinicopathological relationship with TB status.Results: Most common TB status were low grade with 92 cases. Most cases were ≥ 50 years old (64.3%), male (50.7%), located in the left colon (77.5%), histopathological degree low grade (85.9%), depth of invasion on pT3 (61.5%), lymphovascular invasion (LVI) (50.2%), lymph node metastasis (52.6%), stage 3 American Joint Committee on Cancer (AJCC (42.3%), without perineural invasion (PNI) (79.3%) and without distant metastases (82.6%). Statistical analysis test showed that there was a significant relationship between the degree of histopathology, depth of invasion, LVI, lymph node metastasis, and AJCC stage (p 0.001) and tumor location (p = 0.036).Conclusion: TB status was significantly related histopathological degree, LVI, lymph node metastasis, depth of invasion, AJCC stage, and tumor location. TB status was not associated with PNI and distant organ metastases.
{"title":"Relationship between Clinicopathological Profile and Tumor Budding Status in Colorectal Adenocarcinoma at Dr. Cipto Mangunkusumo General National Hospital: A Retrospective Study","authors":"Ika Dhuhani, D. Handjari, N. Rahadiani, E. Krisnuhoni, Marini Stephanie","doi":"10.24871/2332022194-200","DOIUrl":"https://doi.org/10.24871/2332022194-200","url":null,"abstract":"Background: Colorectal adenocarcinoma (CA) is one of the most common malignancies. Tumor budding (TB) status is associated with poor prognosis in patients. Prognosis is influenced by the clinicopathological profile. This study aims to determine the relationship between the clinicopathological profile with TB status in CA at Dr. Cipto Mangunkusumo General National Hospital.Method: A cross-sectional retrospective analytic study using secondary data in the form of cases in large bowel malignancy resection preparations at the Department of Anatomical Pathology in 2019-2021. A total of 213 samples were taken from all cases according to the inclusion and exclusion criteria. Chi square statistical analysis was performed to see the clinicopathological relationship with TB status.Results: Most common TB status were low grade with 92 cases. Most cases were ≥ 50 years old (64.3%), male (50.7%), located in the left colon (77.5%), histopathological degree low grade (85.9%), depth of invasion on pT3 (61.5%), lymphovascular invasion (LVI) (50.2%), lymph node metastasis (52.6%), stage 3 American Joint Committee on Cancer (AJCC (42.3%), without perineural invasion (PNI) (79.3%) and without distant metastases (82.6%). Statistical analysis test showed that there was a significant relationship between the degree of histopathology, depth of invasion, LVI, lymph node metastasis, and AJCC stage (p 0.001) and tumor location (p = 0.036).Conclusion: TB status was significantly related histopathological degree, LVI, lymph node metastasis, depth of invasion, AJCC stage, and tumor location. TB status was not associated with PNI and distant organ metastases. ","PeriodicalId":22564,"journal":{"name":"The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80660918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nikko Darnindro, J. Marsigit, A. Nugroho, A. Sari, M. Taufik, Dieby Adrisyel, Elisabeth Yasmine Wardoyo, Apriliana Ratnaningrum, Danny Darmawan
Background: Liver resection has been associated with high morbidity and mortality. Improvements in surgical, anesthetic techniques, and multidisciplinary collaborations, can reduce post-surgery complications and mortality. This study aims to provide an overview of the perioperative conditions and the treatments after liver resection.Method: A retrospective study of liver resection surgery between 2019-2020 at Fatmawati Hospital.Results: Of the 11 patients, mean age was 49.7 years, with 63.6% being female and mean BMI was 22 kg/m2, hypertension and diabetes mellitus were found in 18.2% and 18.2% of patients respectively. HBsAg reactive was detected in 36.3%. Based on pathology, HCC was found in 54.5%, while 18.2% were metastatic adenocarcinoma. Postoperative hyperglycemia was observed in 90.9%. Increase in AST and ALT 3 upper limit normal were found in 90% and 72.7% of patients. Mean AST and ALT were 408.3 U/L and 246.18 U/L. Mean urine production at 8-, 16-, 24-, and 48-hours post-operative were 757, 1624, 1880 and 1930 cc. Urine production ≤ 500 cc in the first 8 hours was detected in 44.4% of patients, and elevated creatinine levels 50% post-operative occurred at 11.1%, 22.2%, 22.2% at 16, 24, and 48 hours post-op. Renal support therapy was given to 5 of the 11 patients. D-Dimer levels were increased in all patients.Conclusion: Adequate fluid monitoring and metabolic disorders control such as glucose levels, acute kidney injury, coagulation disorders, and bleeding are important things that need to be considered in the perioperative management of liver resection.
{"title":"Clinical, Laboratory, and Perioperative Management Characteristics in Liver Resection Cases in Fatmawati General Hospital","authors":"Nikko Darnindro, J. Marsigit, A. Nugroho, A. Sari, M. Taufik, Dieby Adrisyel, Elisabeth Yasmine Wardoyo, Apriliana Ratnaningrum, Danny Darmawan","doi":"10.24871/2332022210-216","DOIUrl":"https://doi.org/10.24871/2332022210-216","url":null,"abstract":"Background: Liver resection has been associated with high morbidity and mortality. Improvements in surgical, anesthetic techniques, and multidisciplinary collaborations, can reduce post-surgery complications and mortality. This study aims to provide an overview of the perioperative conditions and the treatments after liver resection.Method: A retrospective study of liver resection surgery between 2019-2020 at Fatmawati Hospital.Results: Of the 11 patients, mean age was 49.7 years, with 63.6% being female and mean BMI was 22 kg/m2, hypertension and diabetes mellitus were found in 18.2% and 18.2% of patients respectively. HBsAg reactive was detected in 36.3%. Based on pathology, HCC was found in 54.5%, while 18.2% were metastatic adenocarcinoma. Postoperative hyperglycemia was observed in 90.9%. Increase in AST and ALT 3 upper limit normal were found in 90% and 72.7% of patients. Mean AST and ALT were 408.3 U/L and 246.18 U/L. Mean urine production at 8-, 16-, 24-, and 48-hours post-operative were 757, 1624, 1880 and 1930 cc. Urine production ≤ 500 cc in the first 8 hours was detected in 44.4% of patients, and elevated creatinine levels 50% post-operative occurred at 11.1%, 22.2%, 22.2% at 16, 24, and 48 hours post-op. Renal support therapy was given to 5 of the 11 patients. D-Dimer levels were increased in all patients.Conclusion: Adequate fluid monitoring and metabolic disorders control such as glucose levels, acute kidney injury, coagulation disorders, and bleeding are important things that need to be considered in the perioperative management of liver resection.","PeriodicalId":22564,"journal":{"name":"The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87820860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. A. Trixie, Kirsten Putriani Hartman, D. N. Esterini, Dany Dias, Juan Alessandro Jeremis Maruli Nura Lele
Background: It has been long known that Helicobacter species are one of the leading causes in gastrointestinal diseases. Recently, it is emerging as one of the causes leading to gallbladder diseases, such as gallbladder cancer and gallstones. The aim of this study is to assess the correlation between Helicobacter species and gallbladder cancer and gallstones.Method: This meta-analysis assessed case-control studies from the year 2001 to 2022. A comprehensive literature search was performed in Pubmed, Scopus, Embase, dan Plos One. Review manager 5.4.1, along with the Mantel Haenszel method, was utilized to analyze the data extraction. The methodological index was utilized to assess the risk of bias from the included studies. The odds ratio is calculated with a confidence interval of 95%. P 0.05 was considered significant.Results: Twenty case-control studies from the year 2001 to 2018 with a total number of 2,065 participants were included. We found that there is a low risk of bias and a significant difference between the control group and the experimental group; gallbladder cancer (random effect: OR = 2.38; 95% CI: 1.35–4.19; p = 0.003) and gallstones (fixed effect: OR = 4.17; 95% CI: 2.71– 4.62; p = 0.00001).Conclusion: Results of this meta-analysis demonstrated that the patients with Helicobacter species have an increased risk of gallbladder cancer and gallstones.
{"title":"Helicobacter Species as Possible Risk Factor in Gallbladder Cancer and Gallstones: A Meta-Analysis","authors":"J. A. Trixie, Kirsten Putriani Hartman, D. N. Esterini, Dany Dias, Juan Alessandro Jeremis Maruli Nura Lele","doi":"10.24871/2332022201-209","DOIUrl":"https://doi.org/10.24871/2332022201-209","url":null,"abstract":"Background: It has been long known that Helicobacter species are one of the leading causes in gastrointestinal diseases. Recently, it is emerging as one of the causes leading to gallbladder diseases, such as gallbladder cancer and gallstones. The aim of this study is to assess the correlation between Helicobacter species and gallbladder cancer and gallstones.Method: This meta-analysis assessed case-control studies from the year 2001 to 2022. A comprehensive literature search was performed in Pubmed, Scopus, Embase, dan Plos One. Review manager 5.4.1, along with the Mantel Haenszel method, was utilized to analyze the data extraction. The methodological index was utilized to assess the risk of bias from the included studies. The odds ratio is calculated with a confidence interval of 95%. P 0.05 was considered significant.Results: Twenty case-control studies from the year 2001 to 2018 with a total number of 2,065 participants were included. We found that there is a low risk of bias and a significant difference between the control group and the experimental group; gallbladder cancer (random effect: OR = 2.38; 95% CI: 1.35–4.19; p = 0.003) and gallstones (fixed effect: OR = 4.17; 95% CI: 2.71– 4.62; p = 0.00001).Conclusion: Results of this meta-analysis demonstrated that the patients with Helicobacter species have an increased risk of gallbladder cancer and gallstones.","PeriodicalId":22564,"journal":{"name":"The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72644813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bastomy Eka Rezkita, Ina Agustin Pertiwi, Ismi Cahya Dhelima, D. R. Budiani, Steven Irving
Background: Metabolic syndrome has been associated with chronic inflammation due to the increase of lymphocyte focus on hepatic lobular tissue. Moringa oleifera Lam. is an herbal plant that potentially reduce the inflammation process. This study aims to evaluate the effect of Moringa seed extract (MSE) on hepatic lobularinflammation in rats with hepatic tissue metabolic syndrome (MetS).Method: Twenty-four male Wistar rats (n = 24) were assigned into four groups: one control group (C) and three MetS groups, fed with a high-fat, high-fructose diet (HFHFD) daily for 53 days. After 53 days, respectively, MetS 2 and MetS 3 groups were given 150 and 200 mg/kg MSE. After 28 days of MSE administration, the rats were sacrificed, and then hepatic lobular inflammation measured with lobular inflammation score. The effect of MSE on hepatic lobular inflammation was analyzed with Kruskal-Wallis and Mann-Whitney test.Results: There was a significant difference in hepatic lobular inflammation between four groups (p = 0.000). Mann-Whitney showed a significant difference between C vs. MetS 1, MetS 1 vs. MetS 2, and MetS 1 vs. MetS 3 (p = 0.000), but not significant C vs. MetS 2 (p = 0.364), C vs. MetS 3 (p = 0.109), MetS 2 vs. MetS 3 (p = 0.533).Conclusion: MSE at the dose of 150 mg/kg and 200 mg/kg significantly reduces lobular inflammation in hepatic tissue of MetS rats.
{"title":"Hepatoprotector Effect of Moringa Oleifera Lam. Seeds Extract Through Decrease Liver Inflammation of Rats with Metabolic Syndrome","authors":"Bastomy Eka Rezkita, Ina Agustin Pertiwi, Ismi Cahya Dhelima, D. R. Budiani, Steven Irving","doi":"10.24871/2332022174-179","DOIUrl":"https://doi.org/10.24871/2332022174-179","url":null,"abstract":"Background: Metabolic syndrome has been associated with chronic inflammation due to the increase of lymphocyte focus on hepatic lobular tissue. Moringa oleifera Lam. is an herbal plant that potentially reduce the inflammation process. This study aims to evaluate the effect of Moringa seed extract (MSE) on hepatic lobularinflammation in rats with hepatic tissue metabolic syndrome (MetS).Method: Twenty-four male Wistar rats (n = 24) were assigned into four groups: one control group (C) and three MetS groups, fed with a high-fat, high-fructose diet (HFHFD) daily for 53 days. After 53 days, respectively, MetS 2 and MetS 3 groups were given 150 and 200 mg/kg MSE. After 28 days of MSE administration, the rats were sacrificed, and then hepatic lobular inflammation measured with lobular inflammation score. The effect of MSE on hepatic lobular inflammation was analyzed with Kruskal-Wallis and Mann-Whitney test.Results: There was a significant difference in hepatic lobular inflammation between four groups (p = 0.000). Mann-Whitney showed a significant difference between C vs. MetS 1, MetS 1 vs. MetS 2, and MetS 1 vs. MetS 3 (p = 0.000), but not significant C vs. MetS 2 (p = 0.364), C vs. MetS 3 (p = 0.109), MetS 2 vs. MetS 3 (p = 0.533).Conclusion: MSE at the dose of 150 mg/kg and 200 mg/kg significantly reduces lobular inflammation in hepatic tissue of MetS rats.","PeriodicalId":22564,"journal":{"name":"The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89067755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: The mortality rate in patients with acute liver failure (ALF) and acute on chronic liver failure (ACLF) is still very high. Currently, liver support systems are an alternative therapy in bridging liver transplantation. However, its effectiveness in reducing mortality is still controversial when compared to standard medical therapy (SMT). Our study aims to review the efficacy of liver support system compared to standard medical therapy (SMT) among acute liver failure patients without liver transplantation.Method: We conducted systematic literature searching using PubMed/MEDLINE, EBSCO-CINAHL, ProQuest, and Cochrane databases. Selected articles were examined for duplicates and were screened by abstract and title. Then, we appraised the articles based on the critical appraisal tools from Centre for Evidence-Based Medicine (CEBM) University of OxfordResults: One systematic review and meta-analysis of randomized control trials study was extracted after thorough research. Alhamshi et al showed that extracorporeal liver support has significantly reduced mortality in both ALF and ACLF patients as the primary outcome. Other main findings about adverse events including hepatic encephalopathy, thrombocytopenia, bleeding, and infection were still unclear.Conclusion: The use of liver support system demonstrated better outcome in reducing mortality to standard medical therapy in transplant free patients with liver failure, but best modality recommendation was inconclusive.
{"title":"Liver Support System and Transplant-Free Survival Patients with Liver Failure: An Evidence-Based Case Report","authors":"Aravinda Pravita, Kresna Adhiatma, Juferdy Kurniawan","doi":"10.24871/2322022261-265","DOIUrl":"https://doi.org/10.24871/2322022261-265","url":null,"abstract":"Background: The mortality rate in patients with acute liver failure (ALF) and acute on chronic liver failure (ACLF) is still very high. Currently, liver support systems are an alternative therapy in bridging liver transplantation. However, its effectiveness in reducing mortality is still controversial when compared to standard medical therapy (SMT). Our study aims to review the efficacy of liver support system compared to standard medical therapy (SMT) among acute liver failure patients without liver transplantation.Method: We conducted systematic literature searching using PubMed/MEDLINE, EBSCO-CINAHL, ProQuest, and Cochrane databases. Selected articles were examined for duplicates and were screened by abstract and title. Then, we appraised the articles based on the critical appraisal tools from Centre for Evidence-Based Medicine (CEBM) University of OxfordResults: One systematic review and meta-analysis of randomized control trials study was extracted after thorough research. Alhamshi et al showed that extracorporeal liver support has significantly reduced mortality in both ALF and ACLF patients as the primary outcome. Other main findings about adverse events including hepatic encephalopathy, thrombocytopenia, bleeding, and infection were still unclear.Conclusion: The use of liver support system demonstrated better outcome in reducing mortality to standard medical therapy in transplant free patients with liver failure, but best modality recommendation was inconclusive. ","PeriodicalId":22564,"journal":{"name":"The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88341395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tumor ablation is a minimally invasive approach commonly used in the treatment of liver tumors. Over the last two decades, percutaneous radiofrequency ablation (RFA) has been widely used for primary tumors and small metastases, especially in the liver. Effective treatment of RFA can be accomplished by complete ablation of the tumor accompanied by a margin resection of at least 0.5 cm. One of the commonly used methods is percutaneous radiofrequency ablation. The overall and disease-free survival rate of RFA was found to be more effective than that observed with surgical resection. The success rate of RFA is highly dependent on the precision of tumor targeting, which is influenced by two main factors, such as electrode tip placement and angulation for electrode placement. In this literature review, we will discuss about percutaneous radiofrequency ablation.
{"title":"Purcutaneus Radiofrequency Ablation In Liver Tumor","authors":"Budi Tulaka, B. J. Waleleng, Luciana Rotty","doi":"10.24871/2322022237-243","DOIUrl":"https://doi.org/10.24871/2322022237-243","url":null,"abstract":"Tumor ablation is a minimally invasive approach commonly used in the treatment of liver tumors. Over the last two decades, percutaneous radiofrequency ablation (RFA) has been widely used for primary tumors and small metastases, especially in the liver. Effective treatment of RFA can be accomplished by complete ablation of the tumor accompanied by a margin resection of at least 0.5 cm. One of the commonly used methods is percutaneous radiofrequency ablation. The overall and disease-free survival rate of RFA was found to be more effective than that observed with surgical resection. The success rate of RFA is highly dependent on the precision of tumor targeting, which is influenced by two main factors, such as electrode tip placement and angulation for electrode placement. In this literature review, we will discuss about percutaneous radiofrequency ablation.","PeriodicalId":22564,"journal":{"name":"The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy","volume":"104 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82448198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：